FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283704114> ?p ?o ?g. }

• W4283704114 endingPage "e584" @default.
• W4283704114 startingPage "e573" @default.
• W4283704114 abstract "Management of neutropenic fever in high-risk haematology patients is challenging; there are often few localising clinical features, and diagnostic tests have poor sensitivity and specificity. We aimed to compare how [18F]flurodeoxyglucose ([18F]FDG)-PET-CT scans and conventional CT scans affected the guidance of antimicrobial management and the outcomes of patients with persistent or recurrent neutropenic fever.We did a multicentre, open-label, phase 3, randomised, controlled trial in two tertiary referral hospitals in Australia. We recruited adults aged 18 years or older who were receiving conditioning chemotherapy for haematopoietic stem-cell transplantation or chemotherapy for acute leukaemia and had persistent (>72 h) or recurrent (new fever beyond 72 h of initial onset interspersed with >48 h defervescence) neutropenic fever. Exclusion criteria were pregnancy, allergy to iodinated contrast, or estimated glomerular filtration rate of less than 30 mL/min. Patients were randomly assigned by computer-generated randomisation chart (1:1) to [18F]FDG-PET-CT or conventional CT. Masking was not possible because of the nature of the investigation. Scans were done within 3 days of random assignment. The primary endpoint was a composite of starting, stopping, or changing the spectrum (broadening or narrowing) of antimicrobial therapy-referred to here as antimicrobial rationalisation-within 96 h of the assigned scan, analysed per protocol. This trial is registered with clinicaltrials.gov, NCT03429387, and is complete.Between Jan 8, 2018, and July 23, 2020, we assessed 316 patients for eligibility. 169 patients were excluded and 147 patients were randomly assigned to either [18F]FDG-PET-CT (n=73) or CT (n=74). Nine patients did not receive a scan per protocol, and two participants in each group were excluded for repeat entry into the study. 65 patients received [18F]FDG-PET-CT (38 [58%] male; 53 [82%] White) and 69 patients received CT (50 [72%] male; 58 [84%] White) per protocol. Median follow up was 6 months (IQR 6-6). Antimicrobial rationalisation occurred in 53 (82%) of 65 patients in the [18F]FDG-PET-CT group and 45 (65%) of 69 patients in the CT group (OR 2·36, 95% CI 1·06-5·24; p=0·033). The most frequent component of antimicrobial rationalisation was narrowing spectrum of therapy, in 28 (43%) of 65 patients in the [18F]FDG-PET-CT group compared with 17 (25%) of 69 patients in the CT group (OR 2·31, 95% CI 1·11-4·83; p=0·024).[18F]FDG-PET-CT was associated with more frequent antimicrobial rationalisation than conventional CT. [18F]FDG-PET-CT can support decision making regarding antimicrobial cessation or de-escalation and should be considered in the management of patients with haematological diseases and persistent or recurrent high-risk neutropenic fever after chemotherapy or transplant conditioning.National Health and Medical Research Council Centre of Research Excellence (APP1116876), Melbourne Health foundation, Gilead Research Fellowship grants supported this study." @default.
• W4283704114 created "2022-06-30" @default.
• W4283704114 creator A5007604802 @default.
• W4283704114 creator A5013950863 @default.
• W4283704114 creator A5015511458 @default.
• W4283704114 creator A5016575685 @default.
• W4283704114 creator A5017442411 @default.
• W4283704114 creator A5018838899 @default.
• W4283704114 creator A5023356675 @default.
• W4283704114 creator A5028575111 @default.
• W4283704114 creator A5037683678 @default.
• W4283704114 creator A5038204813 @default.
• W4283704114 creator A5038304654 @default.
• W4283704114 creator A5043112440 @default.
• W4283704114 creator A5054345447 @default.
• W4283704114 creator A5059566329 @default.
• W4283704114 creator A5061556384 @default.
• W4283704114 creator A5061951008 @default.
• W4283704114 creator A5063393123 @default.
• W4283704114 creator A5067655143 @default.
• W4283704114 creator A5069678589 @default.
• W4283704114 creator A5071712855 @default.
• W4283704114 creator A5076595076 @default.
• W4283704114 creator A5078346197 @default.
• W4283704114 date "2022-08-01" @default.
• W4283704114 modified "2023-10-11" @default.
• W4283704114 title "[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial" @default.
• W4283704114 cites W1725388447 @default.
• W4283704114 cites W1974100199 @default.
• W4283704114 cites W1985577062 @default.
• W4283704114 cites W2014713514 @default.
• W4283704114 cites W2039956081 @default.
• W4283704114 cites W2087203965 @default.
• W4283704114 cites W2105525503 @default.
• W4283704114 cites W2115225413 @default.
• W4283704114 cites W2117730870 @default.
• W4283704114 cites W2122544348 @default.
• W4283704114 cites W2132986533 @default.
• W4283704114 cites W2148126683 @default.
• W4283704114 cites W2166734004 @default.
• W4283704114 cites W2243679112 @default.
• W4283704114 cites W2335721167 @default.
• W4283704114 cites W2400922751 @default.
• W4283704114 cites W2471267237 @default.
• W4283704114 cites W2551431216 @default.
• W4283704114 cites W2589011865 @default.
• W4283704114 cites W2661445781 @default.
• W4283704114 cites W2770594484 @default.
• W4283704114 cites W2807392499 @default.
• W4283704114 cites W2809270380 @default.
• W4283704114 cites W2837150463 @default.
• W4283704114 cites W2897974729 @default.
• W4283704114 cites W2914544167 @default.
• W4283704114 cites W2920796502 @default.
• W4283704114 cites W3008229386 @default.
• W4283704114 cites W3126987320 @default.
• W4283704114 doi "https://doi.org/10.1016/s2352-3026(22)00166-1" @default.
• W4283704114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35777413" @default.
• W4283704114 hasPublicationYear "2022" @default.
• W4283704114 type Work @default.
• W4283704114 citedByCount "9" @default.
• W4283704114 countsByYear W42837041142022 @default.
• W4283704114 countsByYear W42837041142023 @default.
• W4283704114 crossrefType "journal-article" @default.
• W4283704114 hasAuthorship W4283704114A5007604802 @default.
• W4283704114 hasAuthorship W4283704114A5013950863 @default.
• W4283704114 hasAuthorship W4283704114A5015511458 @default.
• W4283704114 hasAuthorship W4283704114A5016575685 @default.
• W4283704114 hasAuthorship W4283704114A5017442411 @default.
• W4283704114 hasAuthorship W4283704114A5018838899 @default.
• W4283704114 hasAuthorship W4283704114A5023356675 @default.
• W4283704114 hasAuthorship W4283704114A5028575111 @default.
• W4283704114 hasAuthorship W4283704114A5037683678 @default.
• W4283704114 hasAuthorship W4283704114A5038204813 @default.
• W4283704114 hasAuthorship W4283704114A5038304654 @default.
• W4283704114 hasAuthorship W4283704114A5043112440 @default.
• W4283704114 hasAuthorship W4283704114A5054345447 @default.
• W4283704114 hasAuthorship W4283704114A5059566329 @default.
• W4283704114 hasAuthorship W4283704114A5061556384 @default.
• W4283704114 hasAuthorship W4283704114A5061951008 @default.
• W4283704114 hasAuthorship W4283704114A5063393123 @default.
• W4283704114 hasAuthorship W4283704114A5067655143 @default.
• W4283704114 hasAuthorship W4283704114A5069678589 @default.
• W4283704114 hasAuthorship W4283704114A5071712855 @default.
• W4283704114 hasAuthorship W4283704114A5076595076 @default.
• W4283704114 hasAuthorship W4283704114A5078346197 @default.
• W4283704114 hasConcept C126322002 @default.
• W4283704114 hasConcept C141071460 @default.
• W4283704114 hasConcept C203092338 @default.
• W4283704114 hasConcept C2776694085 @default.
• W4283704114 hasConcept C2777063308 @default.
• W4283704114 hasConcept C2778850193 @default.
• W4283704114 hasConcept C2779310458 @default.
• W4283704114 hasConcept C535046627 @default.
• W4283704114 hasConcept C71924100 @default.
• W4283704114 hasConceptScore W4283704114C126322002 @default.
• W4283704114 hasConceptScore W4283704114C141071460 @default.
• W4283704114 hasConceptScore W4283704114C203092338 @default.

• next